https://www.selleckchem.com/pr....oducts/Erlotinib-Hyd
If≥17 patients achieved benefit, the null CBR of 20% would be rejected at a nominal 5% alpha level. Secondary end points included progression-free survival (PFS), overall survival (OS), quality of lifeand serum biomarkers. Fifty-six patients were enrolled from May 2015 to February 2019 and are included in the intention-to-treat analysis. Median PFS was 3.67 (2.62-7.25) months. Median OS was 14.16 (95% confidence interval [CI] 8.4-NR) months, CBR=39.29% (22/56)(CI=0.265-0.533, p=0.0007). No new or unexpected adverse event